Safe Use of Contrast Media in Radiology (Clinical Guidelines)
V. E. Sinitsyn,
I. E. Tyurin,
N. L. Shimanovskiy,
G. G. Karmazanovskiy,
V. G. Bychenko,
N. A. Rubtsova,
D. A. Filatova https://doi.org/10.20862/0042-4676-2023-104-6-363-384
Abstract
In recent years, the frequency of contrast-enhanced radiological studies has increased significantly, and the issues of their selection and rational use do not lose their relevance. These methodological recommendations represent a complete up-to-date guide for using contrast agents (CA) in radiology. Types of currently used CA in computed tomography, magnetic resonance imaging, and ultrasound examinations are described. Safety rules for injection of each CA type are systematized, the principles of dosing and possible side effects are explained. In addition, it is important to highlight the issues of interactions between CA and other drugs that patient might take, in particular, the possible deterioration of renal function when using CA in diabetes mellitus patients taking metformin. It should be noted that these recommendations have undergone significant changes in recent years. Also questionnaire templates for patients prior to the contrast-enhanced study are given in the supplements. The methodological guidelines are based on current publications of international experts on CA use in radiology as well as on the data of two major guidelines: American College of Radiologists (ACR) Guidelines (2023) and European Society of Urogenital Radiology (ESUR) Safety Recommendations (2018, version 10). Thus, the information presented is validated, which provides grounds for its application in real clinical practice. The guidelines will be actualized as new scientific evidence becomes available, but to date they appear to be the most relevant.
About the Authors
V. E. Sinitsyn
Lomonosov Moscow State University
Russian Federation
Russian Federation
Valentin Е. Sinitsyn, Dr. Med. Sc., Professor, Chief of Chair of Radiology, Faculty of Fundamental Medicine, Head of Department of Radiology, Medical Scientific and Educational Center
Lomonosovskiy prospekt, 27, corp. 10, Moscow, 119991
I. E. Tyurin
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Igor Е. Tyurin, Dr. Med. Sc., Professor, Chief of Chair of Radiology
ul. Barrikadnaya, 2, str. 1, Moscow, 123995
N. L. Shimanovskiy
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Nikolay L. Shimanovskiy, Dr. Med. Sc., Professor, Corresponding Member of RAS, Chief of Chair of Molecular Pharmacology and Radiobiology named after Academician P.V. Sergeev
ul. Ostrovityanova, 1, Moscow, 117997
G. G. Karmazanovskiy
Pirogov Russian National Research Medical University; Vishnevsky National Medical Research Center of Surgery
Russian Federation
Russian Federation
Grigoriy G. Karmazanovskiy, Dr. Med. Sc., Professor, Corresponding Member of RAS, Professor, Chair of Radiation Diagnostics and Therapy; Head of Department of Radiation Diagnostics and Treatment
ul. Ostrovityanova, 1, Moscow, 117997; ul. Bolshaya Serpukhovskaya, 27, Moscow, 117997
V. G. Bychenko
Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology
Russian Federation
Russian Federation
Vladimir G. Bychenko, Radiologist, Head of Department of Radiation Diagnostics
ul. Akademika Oparina, 4, Moscow, 117997
N. A. Rubtsova
Herzen Moscow Scientific Research Oncological Institute – branch of National Medical Research Center for Radiology
Russian Federation
Russian Federation
Natalia А. Rubtsova, Dr. Med. Sc., Head of Department of Radiation Diagnostics
Vtoroy Botkinskiy proezd, 3, Moscow, 125284
D. A. Filatova
Lomonosov Moscow State University
Russian Federation
Russian Federation
Daria А. Filatova, Radiologist, Postgraduate, Chair of Radiology, Faculty of Fundamental Medicine
Lomonosovskiy prospekt, 27, corp. 10, Moscow, 119991
References
1. Karmazanovskiy GG, Shimanovskiy NL. Contrast agents for radiation diagnostics. Guide. Мoscow: GEOTAR-Media; 2022: 672 pp (in Russ).
2. Hammerstingl RM. Abdominal imaging: use of highconcentration contrast media. In: Marchal G, Vogl TJ, Heiken JP, Rubin GD (Eds). Multidetector-row computed tomography. 1st ed. Milano: Springer; 2005: 49–62. https://doi.org/10.1007/88-470-0363-6_8.
3. Kim T, Murakami T, Takahashi S, et al. Pancreatic CT imaging: effects of different injection rates and doses of contrast material. Radiology. 1999; 212(1): 219–25. https://doi.org/10.1148/radiology.212.1.r99jl06219.
4. Kopka L, Funke M, Fischer U, et al. Parenchymal liver enhancement with bolus-triggered helical CT: preliminary clinical results. Radiology. 1995; 195(1): 282–4. https://doi.org/10.1148/radiology.195.1.7892486.
5. Silverman PM, Brown B, Wray H, et al. Optimal contrast enhancement of the liver using helical (spiral) CT: value of SmartPrep. AJR Am J Roentgenol. 1995; 164(5): 1169–71. https://doi.org/10.2214/ajr.164.5.7717226.
6. Shimanovskiy NL. Contrast media: a guide to rational application. Мoscow: GEOTAR-Media; 2009: 464 pp (in Russ).
7. Elsebaie N, Abdelzaher A, Gamaleldin O. Atypical intracranial aneurysms: spectrum of imaging findings in computed tomography and magnetic resonance imaging. Clin Imaging. 2022; 83: 1–10. https://doi.org/10.1016/j.clinimag.2021.12.003.
8. Schultz J, van den Hoogen I, Kuneman JH, et al. Coronary computed tomography angiography-based endothelial wall shear stress in normal coronary arteries. Int J Cardiovasc Imaging. 2023; 39(2): 441–50. https://doi.org/10.1007/s10554-022-02739-0.
9. Carr DH, Brown J, Bydder GM, et al. Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients. AJR Am J Roentgenol. 1984; 143(2): 215–24. https://doi.org/10.2214/ajr.143.2.215.
10. Niendorf HP, Haustein J, Cornelius I, et al. Safety of gadoliniumDTPA: extended clinical experience. Magn Reson Med. 1991; 22(2): 222–8. https://doi.org/10.1002/mrm.1910220212.
11. Adolph E, Holdt-Lehmann B, Chatterjee T, et al. Renal Insufficiency Following Radiocontrast Exposure Trial (REINFORCE): a randomized comparison of sodium bicar-bonate versus sodium chloride hydration for the prevention of contrastinduced nephropathy. Coron Artery Dis. 2008; 19(6): 413–9. https://doi.org/10.1097/MCA.0b013e3283021ac6.
12. Bolz KD, Skalpe IO, Gutteberg TJ. Iohexol and metrizoate in urography in children. Comparison between a non-ionic and an ionic contrast medium. Acta Radiol Diagn (Stockh). 1984; 25(2): 155–8. https://doi.org/10.1177/028418518402500213.
13. ACR Manual on Contrast Media. Available at: https://www.acr.org/Clinical-Resources/Contrast-Manual (accessed 03.02.2024).
14. European Society of Urogenital Radiology. Available at: https://www.esur.org/ (accessed 03.02.2024).
15. Maddox TG. Adverse reactions to contrast material: recognition, prevention, and treatment. Am Fam Physician. 2002; 66(7): 1229–34.
16. Thomsen HS, Morcos SK. Contrast Media Safety Committee of European Society of Urogenital Radiology. Management of acute adverse reactions to contrast media. Eur Radiol. 2004; 14(3): 476–81. https://doi.org/10.1007/s00330-003-2214-z.
17. Schopp JG, Iyer RS, Wang CL, et al. Allergic reactions to iodinated contrast media: premedication considerations for patients at risk. Emerg Radiol. 2013; 20(4): 299–306. https://doi.org/10.1007/s10140-012-1081-9.
18. Bartlett MJ, Bynevelt M. Acute contrast reaction management by radiologists: a local audit study. Australas Radiol. 2003; 47(4): 363–7. https://doi.org/10.1046/j.1440-1673.2003.01203.x.
19. Bush WH, Swanson DP. Acute reactions to intravascular contrast media: types, risk factors, recognition, and specific treatment. AJR Am J Roentgenol. 1991; 157(6): 1153–61. https://doi.org/10.2214/ajr.157.6.1950858.
20. Dillman JR, Ellis JH, Cohan RH, et al. Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v. contrast media in children and adults. AJR Am J Roentgenol. 2007; 189(6): 1533–8. https://doi.org/10.2214/AJR.07.2554.
21. Webb J, Stacul F, Thomsen HS, et al. Late adverse reactions to intravascular iodinated contrast media. Eur Radiol. 2003; 13(1): 181–4. https://doi.org/10.1007/s00330-002-1650-5.
22. Hosoya T, Yamaguchi K, Akutsu T, et al. Delayed adverse reactions to iodinated contrast media and their risk factors. Radiat Med. 2000; 18(1): 39–45.
23. Ledneva E, Karie S, Launay-Vacher V, et al. Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. Radiology. 2009; 250(3): 618–28. https://doi.org/10.1148/radiol.2503080253.
24. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol. 2008; 43(2): 141–4. https://doi.org/10.1097/RLI.0b013e31815a3407.
25. Schieda N, Blaichman JI, Costa AF, et al. Gadolinium-based contrast agents in kidney disease: comprehensive review and clinical practice guideline issued by the Canadian Association of Radiologists. Can Assoc Radiol J. 2018; 9(2): 136–50. https://doi.org/10.1016/j.carj.2017.11.002.
26. Leidig-Bruckner G. Iodinated contrast medium in patients with thyroid disorders. Radiologe. 2019; 59(5): 413–24 (in German). https://doi.org/10.1007/s00117-019-0520-y.
27. Laurie AJ, Lyon SG, Lasser EC. Contrast material iodides: potential effects on radioactive iodine thyroid uptake. J Nucl Med. 1992; 33(2): 237–8.
28. Nygaard B, Nygaard T, Jensen LI, et al. Iohexol: effects on uptake of radioactive iodine in the thyroid and on thyroid function. Acad Radiol. 1998; 5(6): 409–14. https://doi.org/10.1016/s1076-6332(98)80026-3.
29. Davenport MS, Perazella MA, Yee J, et al. Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2020; 294(3): 660–8. https://doi.org/10.1148/radiol.2019192094.
30. Sinitsin VE, Filatova DA, Mershina EA. Contrast-induced acute renal injury: the modern state of issue. Medical Visualization. 2022; 26(1): 27–39 (in Russ). https://doi.org/10.24835/10.24835/1607-0763-1088.
31. Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017; 389(10076): 1312–22. https://doi.org/10.1016/S0140-6736(17)30057-0.
32. Sadat U. Radiographic contrast-media-induced acute kidney injury: pathophysiology and prophylactic strategies. ISRN Radiol. 2013; 2013: e496438. https://doi.org/10.5402/2013/496438.
33. van der Molen A, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury – Part 1: Definition, clinical features, incidence, role of contrast medium and risk factors: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2018; 28(7): 2845–55. https://doi.org/10.1007/s00330-017-5246-5.
34. Vogt B, Ferrari P, Schönholzer C, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med. 2001; 111(9): 692–8. https://doi.org/10.1016/s0002-9343(01)00983-4.
35. Younathan CM, Kaude JV, Cook MD, et al. Dialysis is not indicated immediately after administration of nonionic contrast agents in patients with end-stage renal disease treated by maintenance dialysis. AJR Am J Roentgenol. 1994; 163(4): 969–71. https://doi.org/10.2214/ajr.163.4.8092045.
36. Younathan CM, Kaude JV, Cook MD, et al. Contrast medium extravasation injury: guidelines for prevention and management. Eur Radiol. 2002; 12(11): 2807–12. https://doi.org/10.2214/ajr.163.4.8092045.
37. Nawaz S, Cleveland T, Gaines PA, et al. Clinical risk associated with contrast angiography in metformin treated patients: a clinical review. Clin Radiol. 1998; 53(5): 342–4. https://doi.org/10.1016/s0009-9260(98)80005-6.
38. Puac P, Rodríguez A, Vallejo C, et al. Safety of contrast material use during pregnancy and lactation. Magn Reson Imaging Clin N Am. 2017; 25(4): 787–97. https://doi.org/10.1016/j.mric.2017.06.010.
39. Webb J, Thomsen HS, Morcos SK, et al. The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol. 2005; 15(6): 1234–40. https://doi.org/10.1007/s00330-004-2583-y.
40. van Welie N, Portela M, Kim Dreyer K, et al. Iodine contrast prior to or during pregnancy and neonatal thyroid function: a systematic review. Eur J Endocrinol. 2021; 184(1): 189–98. https://doi.org/10.1530/EJE-20-0627.
41. Rozenfeld MN, Podberesky DJ. Gadolinium-based contrast agents in children. Pediatr Radiol. 2018; 48(9): 1188–96. https://doi.org/10.1007/s00247-018-4165-1.
Review
For citations:
Sinitsyn V.E., Tyurin I.E., Shimanovskiy N.L., Karmazanovskiy G.G., Bychenko V.G., Rubtsova N.A., Filatova D.A. Safe Use of Contrast Media in Radiology (Clinical Guidelines). Journal of radiology and nuclear medicine. 2023;104(6):363-384. (In Russ.) https://doi.org/10.20862/0042-4676-2023-104-6-363-384
Views:
3288
Email this article 